The pharmacoeconomic benefits of cholesterol reduction.
Recent studies show that cholesterol-lowering therapy can reduce morbidity and mortality in hypercholesterolemic patients without preexisting coronary heart disease (primary prevention) and with coronary heart disease (secondary prevention). The high cost of treatment per event prevented, especially for primary prevention, raises concerns about widespread use of cholesterol-lowering therapy. Does cholesterol reduction reduce utilization of healthcare resources, and can society afford to pay for reducing cholesterol in all patients with hypercholesterolemia, irrespective of risk factors? Is cost-effectiveness of therapy affected by differing cholesterol levels, age of the patients, the duration of therapy, or the presence of risk factors? Current pharmacoeconomic studies support the use of the statins for secondary prevention, and primary prevention in high-risk patients, and provide key information for policy decision making in the treatment of patients with hypercholesterolemia.
Gonzalez
E R
ER
Virginia Commonwealth University, Richmond 23298, USA.
D002792:Cholestyramine Resin / Q000191:economics* / Q000627:therapeutic use; D003327:Coronary Disease / Q000150:complications / Q000517:prevention & control; D017281:Cost of Illness; D003362:Cost-Benefit Analysis; D016527:Drug Costs; D017048:Health Care Costs / Q000706:statistics & numerical data*; D006760:Hospitalization / Q000706:statistics & numerical data; D006801:Humans; D006937:Hypercholesterolemia / Q000097:blood / Q000150:complications / Q000188:drug therapy* / Q000191:economics*; D012307:Risk Factors; D014481:United States